New hope for tough bone cancers: testing a powerful drug duo
NCT ID NCT04803877
Summary
This study is testing whether combining two existing drugs, regorafenib and nivolumab, can better control advanced osteosarcoma (a type of bone cancer) that has come back or stopped responding to standard treatments. It will involve about 48 patients, including children and adults, to see if the combination helps keep the cancer from growing for longer than one of the drugs alone has in the past. The main goal is to see if more patients are progression-free at 4 months compared to historical data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Cincinnati Children's
Cincinnati, Ohio, 45229, United States
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Oregon Health and Sciences University
Portland, Oregon, 97239, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.